ABUS Arbutus Biopharma Corp.

Arbutus to Participate in October Investor Conferences

Arbutus to Participate in October Investor Conferences

WARMINSTER, Penn., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commercializing a cure for people with chronic hepatitis B virus (HBV) infection, as well as therapies to treat coronaviruses (including COVID-19), today announced that the Company will participate in the following October investor conferences:

Chardan’s 5th Annual Genetic Medicines Conference – Virtual (October 4-5, 2021)

  • Fireside Chat: Tuesday, October 5, 2021 at 4:30 pm ET
  • Presenters: William Collier, President and Chief Executive Officer; Dr. Michael Sofia, Chief Scientific Officer; Dr. Gaston Picchio, Chief Development Officer; and David Hastings, Chief Financial Officer

H.C. Wainwright Hepatitis B Virus (HBV) Virtual Conference (October 13, 2021)

  • Fireside Chat: Wednesday, October 13, 2021 at 1:00 pm ET
  • Presenters: William Collier, Dr. Michael Sofia, Dr. Gaston Picchio, and David Hastings

The live webcast links for the fireside chats can be accessed through the Investors section of Arbutus' website at . An archived replay of the webcast will be available on the Company’s website after the conference.

About Arbutus

Arbutus Biopharma Corporation is a publicly traded (Nasdaq: ABUS) biopharmaceutical company primarily focused on discovering, developing and commercializing a cure for people with chronic hepatitis B virus (HBV) infection. The Company is advancing multiple product candidates with distinct mechanisms of action that it believes have the potential to provide a new curative regimen for chronic HBV infection. Arbutus has also initiated a drug discovery and development effort for treating coronaviruses (including COVID-19). For more information, visit .



Contact Information

Investors and Media

William H. Collier

President and CEO

Phone: 267-469-0914

Email:

Lisa M. Caperelli

Vice President, Investor Relations

Phone: 215-206-1822

Email:



EN
28/09/2021

Underlying

ABUSArbutus Biopharma Corp.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Arbutus Biopharma Corp.

 PRESS RELEASE
Free
ABUS Arbutus Biophar...

Arbutus Reports Second Quarter 2025 Financial Results and Provides Cor...

Arbutus Reports Second Quarter 2025 Financial Results and Provides Corporate Update Q2 total revenue of $10.7M includes previously-deferred revenue following reacquisition of Greater China rights to imdusiran Dr. Roger Sawhney joins the Arbutus Board of Directors following resignation of Anuj Hasija Dr. Harry Janssen joins the Arbutus Scientific Advisory Board Strong financial position with cash, cash equivalents and marketable securities of $98.1M WARMINSTER, Pa., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-s...

August 6, 2025 1 EN
 PRESS RELEASE
Free
ABUS Arbutus Biophar...

Arbutus Reacquires Greater China Rights to Imdusiran and Announces Sci...

Arbutus Reacquires Greater China Rights to Imdusiran and Announces Scientific Advisory Board with Late-Stage Clinical Focus Qilu Pharmaceutical and Arbutus mutually agree to conclude strategic partnership for imdusiran in Greater China Drs. Jordan Feld, Ed Gane, Anna Lok, Mark Sulkowski and Man-Fung Yuen join Arbutus Scientific Advisory Board WARMINSTER, Pa., June 25, 2025 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today announced that it has reacquired China ri...

June 25, 2025 1 EN
 PRESS RELEASE
Free
ABUS Arbutus Biophar...

Arbutus Reports First Quarter 2025 Financial Results and Provides Corp...

Arbutus Reports First Quarter 2025 Financial Results and Provides Corporate Update Imdusiran combination therapy has functionally cured 8 patients with chronic hepatitis B (cHBV) to date, including 2 patients who received no interferon AB-101, oral small-molecule PD-L1 inhibitor, shown generally safe and well-tolerated with evidence of high receptor occupancy in Phase 1a/1b Andrew J. Sung joins Arbutus as General Counsel, bringing more than $28 billion in life sciences deal experience Strong financial position with cash, cash equivalents and marketable securities of $113M WARMINSTER, Pa...

May 14, 2025 1 EN
 PRESS RELEASE
Free
ABUS Arbutus Biophar...

Arbutus Presents Clinical Trial Data from its Two HBV Assets, Imdusira...

Arbutus Presents Clinical Trial Data from its Two HBV Assets, Imdusiran and AB-101, at the European Association for the Study of the Liver (EASL) Congress 2025 Data highlighted in late-breaker poster presentation shows that imdusiran achieves functional cure in chronic hepatitis B (cHBV) patients when combined with VTP-300 and low dose nivolumab In a Phase 1a/1b clinical trial, AB-101, an oral PD-L1 inhibitor, has shown to be generally safe and well-tolerated with evidence of high receptor occupancy and no liver dysfunction in cHBV patients WARMINSTER, Pa., May 07, 2025 (GLOBE NEWSWIRE)...

May 7, 2025 1 EN
 PRESS RELEASE
Free
ABUS Arbutus Biophar...

Arbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025

Arbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025 Five abstracts accepted for poster presentations WARMINSTER, Pa., April 23, 2025 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today announced that five abstracts, including one late-breaker, have been accepted for presentation at the European Association for the Study of the Liver (EASL) Congress 2025 taking place May 7 - 10, 2025 in Amsterdam, Netherlands. The following abstracts will be presented ...

April 23, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch